Feeds:
Posts
Comments

Archive for the ‘CRISPR/Cas9 & Gene Editing’ Category

SAVE up to $200! CRISPR: Mechanisms to Applications (part of Discovery on Target Sept. 19-22 in Boston): Register TODAY

UPDATED on 9/13/2016

CRISPR: Mechanisms to Applications (part of Discovery on Target Sept. 19-22 in Boston): Register by August 19 and SAVE up to $200!

Reporter: Aviva Lev-Ari, PhD, RN

DOT-438x219-Sept-in-Boston-1_0819

 


Join us September 19-22, 2016 in Boston, MA to network with your peers and industry leaders while exploring emerging “hot” targets for the pharmaceutical industry at CHI’s 14th Annual Discovery on Target – The Industry’s Preeminent Event on Novel Drug Targets.

The advance savings discount has been extended until this Friday, August 19. Don’t miss your final opportunity to save up to $200 off your conference registration. View the final program and register today: http://www.DiscoveryOnTarget.com

About Discovery on Target:
Discovery on Target showcases current and emerging “hot” targets for the pharmaceutical industry. Spanning four days, the event showcases current and emerging “hot” targets for the pharmaceutical industry. Over 1,100+ attendees (from 26 countries) composed of scientists/technologists, executives, directors, and managers from biopharma, academic, and healthcare organizations participate annually. The 2016 event is comprised of 300+ speakers, 17 conference tracks, 1 training seminar, 5 symposia, 17 short courses, 50+ interactive breakout discussion groups, an exhibit hall of 50+ companies, 100+ posters, and dedicated networking sessions.

See also

CHI’s 14th Annual Discovery on Target: Preliminary Agenda Available and Exclusive Discount to attend Boston’s Discovery on Target (September 19-22, 2016)

https://pharmaceuticalintelligence.com/2016/05/11/chis-14th-annual-discovery-on-target-preliminary-agenda-available-and-exclusive-discount-to-attend-bostons-discovery-on-target-september-2016/

Understanding CRISPR: Mechanisms and Applications: CHI, September 19-22, 2016, Westin Boston Waterfront, Boston

Preliminary Agenda Available and Exclusive Discount to attend Understanding CRISPR: Mechanisms to Applications Symposium in Boston (September 19, 2016)

https://pharmaceuticalintelligence.com/2016/04/06/understanding-crispr-mechanisms-and-applications-chi-september-19-22-2016-westin-boston-waterfront-boston/

Announcement from LPBI Group: key code LPBI16 for Exclusive Discount to attend Boston’s Discovery on Target (September 19-22, 2016, CRISPR: Mechanisms to Applications on 9/19/2016)

https://pharmaceuticalintelligence.com/2016/05/13/announcement-from-lpbi-group-key-code-lpbi16-for-exclusive-discount-to-attend-bostons-discovery-on-target-september-2016/

Read Full Post »

See Who’s Attending CHI’s “Discovery on Target” USE key code LPBI16 for Exclusive Discount to attend Boston’s September 19-22, 2016 & CRISPR: Mechanisms to Applications on 9/19/2016

Reporter: Aviva Lev-Ari, PhD, RN

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group is a Media Partner of CHI for CHI’s 14th Annual Discovery on Target taking place September 19 – 22, 2016 in Boston.

As a proud partner of this event, Leaders in Pharmaceutical Business Intelligence Group has secured a special discounted price for you to attend, resulting in a $200 discount on a commercial registration and $100 discount on an academic registration!

*This offer is valid for new registrants only, does not apply to previously registered attendees or short courses, and cannot be combined with any other offer. You must mention key code LPBI16 to receive this discount.

Don’t miss your opportunity to network with 1,100+ of your peers at this year’s event. Special early registration savings are currently available – You must mention key code LPBI16 to receive this discount.

AGENDA and Registration Link

http://www.DiscoveryOnTarget.com

For sponsorship & exhibit information, please contact: Jon Stroup, Sr Business Development Manager,
(+1) 781-972-5483, jstroup@healthtech.com

 

 

See Who’s Attending Discovery on Target; Deadline to Save Extended

Advance Registration Savings Extended to This Friday!

Register Now to Save

We are just five weeks away from this year’s Discovery on Target in Boston. Spanning four days, the event showcases current and emerging “hot” targets for the pharmaceutical industry. Join us September 19-22 and choose from 17 conference tracks, 1 training seminar, 6 symposia and 17 short courses. Don’t miss an exhibit hall of 50+ companies, 135+ posters, and dedicated networking sessions.  

Below is a partial list of confirmed attendees.

View the final agenda at: DiscoveryOnTarget.com

Download Brochure

JOIN THIS GROWING LIST OF PARTICIPANTS!

(Below is a partial list of confirmed attendees)

Company

Aaron Diamond AIDS Research Ctr

Ab Initio Biotherapeutics Inc

AbbVie Bioresearch Ctr

AbbVie Inc

AbbVie Inc

Abcam Inc

Abcam Inc

Abcellera

Ablynx NV

Academia Sinica

Acetylon Pharmaceuticals Inc

Acetylon Pharmaceuticals Inc

Acetylon Pharmaceuticals Inc

Acetylon Pharmaceuticals Inc

Acetylon Pharmaceuticals Inc

Active Motif Inc

Active Motif Inc

Active Motif Inc

AdAlta Pty Ltd

Adimab LLC

Aerpio Therapeutics

Affimed

Affimed

Affimed

Affymetrix eBioscience

Agios Pharmaceuticals

Ajou University

Al Azhar University

Albany Molecular Research Inc

Alkermes Inc

Almac Discovery

ALPCO Diagnostics American Lab Products Co

ALPCO Diagnostics American Lab Products Co

ALPCO Diagnostics American Lab Products Co

Amgen China R&D Ctr

Amgen Inc

Amgen Inc

Amgen Inc

Amgen Inc

Amrita Therapeutics

Ann & Robert H Lurie Childrens Hospital

Antibody Solutions

AOBiome LLC

Applied StemCell Inc

Applied StemCell Inc

Applied StemCell Inc

Arizona State University

ART BioScience Ltd

Asahi Kasei Pharma Co Ltd

AssayQuant Technologies Inc

Astellas Institute for Regenerative Medicine AIRM

Astellas Pharma Inc

Astellas Pharma Inc

Astex Pharmaceuticals

AstraZeneca

AstraZeneca Pharmaceuticals

AstraZeneca Pharmaceuticals

AstraZeneca Pharmaceuticals

AstraZeneca Pharmaceuticals

AstraZeneca R&D

Atlas Venture

Atlas Venture

Avacta Life Sciences

Avacta Life Sciences

Avanti Biosciences

AvidBiotics

AxioMx Inc

Bayer

Baylor College of Medicine

Baylor College of Medicine

BC Cancer Agcy

BellBrook Labs LLC

BellBrook Labs LLC

BellBrook Labs LLC

BellBrook Labs LLC

BellBrook Labs LLC

Ben Gurion University of the Negev

Bio Prodict BV

BIOCAD

Biogen

Biogen

Biogen

Biogen

Biogen

Biogen

Biogen

Biomodels LLC

BioMotiv LLC

BiOptix Inc

BiOptix Inc

biose

Blueprint Medicines

Boehringer Ingelheim Austria GmbH

Boehringer Ingelheim Pharmaceuticals Inc

Boehringer Ingelheim Pharmaceuticals Inc

Boston Biochem

Boston Biochem

Boston Micromachines Corp

Brigham & Womens Hospital

Brigham & Womens Hospital

Brigham & Womens Hospital

Brigham & Womens Hospital

Bristol Myers Squibb Co

Bristol Myers Squibb Co

Broad Institute

Broad Institute

Broad Institute

C3 Jian Inc

C4 Therapeutics Inc

C4 Therapeutics Inc

C4 Therapeutics Inc

Calithera Biosciences Inc

Cambridge Healthtech Institute

Cambridge Healthtech Institute

Cambridge Healthtech Institute

Cambridge Healthtech Institute

Cancer Research Technology Ltd

Cancer Research Technology Ltd

Capsugel

CDI Labs Inc

Celgene

Celgene Cellular Therapeutics

Celgene Corp

Celgene Corp

Celgene Corp

Cellceutix Corp

Cellecta Inc

Cellecta Inc

Cellecta Inc

Cellecta Inc

Cellectis SA

CellFree Sciences Co Ltd

CellFree Sciences Co Ltd

Charles River Labs

ChemBridge Corp

Childrens Hospital of Philadelphia

Childrens Natl Health System

Chugai Pharmaceutical Co Ltd

Chugai Pharmaceutical Co Ltd

CISbio Bioassays

City of Hope Beckman Research Institute

Clasado BioSciences

Clorox Co

Cold Spring Harbor Lab

Collaborative Drug Discovery Inc

Collaborative Drug Discovery Inc

Collaborative Drug Discovery Inc

Collaborative Drug Discovery Inc

Confo Therapeutics

Constellation Pharmaceuticals

Constellation Pharmaceuticals

Contract Pharmaceuticals Ltd

ConverGene LLC

Cornerstone Pharmaceuticals Inc

Corning Inc

CRELUX GmbH

CRISPR Therapeutics

Crystal Bioscience

Crystal Bioscience

CrystalGenomics Inc

Cures Within Reach

Da Volterra

Daegu Gyeongbuk Institute of Science & Technology

Daegu Gyeongbuk Institute of Science & Technology

Daegu Gyeongbuk Institute of Science & Technology

Dana Farber Cancer Institute

Dana Farber Cancer Institute

Dana Farber Cancer Institute

Dana Farber Cancer Institute

Dartmouth College

DDNEWS

Defense Threat Reduction Agcy

Delphi BioMedical Consultants LLC

Dermira Inc

Desktop Genetics Ltd

Diagenode Inc

Diagenode Inc

DiCE Molecules SV LLC

DiscoverX Corp

DiscoverX Corp

DiscoverX Corp

DiscoverX Corp

DiscoverX Corp

DiscoverX Corp

DiscoverX Corp

DiscoverX Corp

Diversigen Inc

Diversigen Inc

DrBonnie360

Duke University

Duke University

Ehime University

Eli Lilly & Co

Eli Lilly & Co

ELIGO Bioscience

EMD Serono

EMD Serono R&D Institute

EMD Serono R&D Institute

Emory University

Ensemble Therapeutics

EpiBiome Inc

EpiCypher Inc

EpiCypher Inc

EpiZyme Inc

EpiZyme Inc

EpiZyme Inc

EpiZyme Inc

EpiZyme Inc

EpiZyme Inc

Euroscreen SA

Evelo Biosciences

Evogene Ltd

Evolve Biosystems

Excelra Knowledge Solutions Pvt Ltd

Eyegate Pharmaceuticals Inc

F Hoffmann La Roche AG

Fate Therapeutics Inc

Fate Therapeutics Inc

Fate Therapeutics Inc

FDA

FLX Bio Inc

FORMA Therapeutics Inc

FORMA Therapeutics Inc

FORMA Therapeutics Inc

FORMA Therapeutics Inc

FORMA Therapeutics Inc

Fox Chase Cancer Ctr

Fred Hutchinson Cancer Research Ctr

Gachon University Gil Hospital

GE Healthcare Dharmacon Inc

GE Healthcare Dharmacon RNAi & Gene Expression

GE Healthcare Dharmacon RNAi & Gene Expression

Genentech Inc

Genentech Inc

Genentech Inc

Genentech Inc

Genentech Inc

Genentech Inc

Genentech Inc

Genomic Healthcare Strategies

GenScript USA Inc

George Washington University

George Washington University

George Washington University

German Cancer Research Ctr

Ghent University

GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline

GlaxoSmithKline

Global Prior Art

Global Prior Art

Glycostem Therapeutics

Gmax Biopharm LLC

Green Cross LabCell

Harbour Antibodies

Harbour Antibodies

Harvard Medical School

Harvard Medical School

Harvard Medical School

Harvard Medical School

Harvard Medical School

Harvard Medical School

Harvard Medical School

Harvard Medical School

Harvard University

Helmholtz Zentrum Muenchen GmbH

Heptares Therapeutics Ltd

Hiroshima University

Homology Medicines Inc

Homology Medicines Inc

Human Longevity Inc

Hummingbird Bioscience Pte Ltd

Hummingbird Bioscience Pte Ltd

Icahn School of Medicine at Mount Sinai

Immunomedics Inc

Imperial College London

Incyte Corp

Incyte Corp

Innovative Targeting Solutions Inc

Institut de Recherche Pierre Fabre

Institut Pasteur

Integral BioSystems LLC

Integral Molecular Inc

Integral Molecular Inc

Integral Molecular Inc

Inventages Venture Capital

inVentiv Health

iVeena Inc

Janssen R&D

Janssen R&D

Janssen R&D LLC

Janssen R&D LLC

Janssen R&D LLC

JDRF

JDRF

Johns Hopkins University

Johns Hopkins University

Johnson & Johnson Pharmaceutical R&D

JT Central Pharmaceutical Research Institute

Juntendo University

Kadmon Corp LLC

Karus Therapeutics Ltd

Karyopharm Therapeutics Inc

Kezar Life Sciences

King Saud University

Kissei Pharmaceutical Co Ltd

KIST

Korea Basic Science Institute

Kyowa Hakko Kirin Co Ltd

LakePharma Inc

Landspitali University Hospital

LayerBio Inc

Lead Pharma

Leaders in Pharmaceutical Business Intelligence

Leaders in Pharmaceutical Business Intelligence

LEO Pharma AS

Life Chemicals Inc

Life Chemicals Inc

Life Technologies Corp

Lonza Walkersville Inc

Lundbeck

Madrigal Pharmaceuticals

Massachusetts Eye & Ear Infirmary

Massachusetts General Hospital

Massachusetts General Hospital

Massachusetts General Hospital

Massachusetts Institute of Technology

Massachusetts Institute of Technology

Massachusetts Institute of Technology

Massachusetts Institute of Technology

Massachusetts Institute of Technology

Massey University

McGill University

McMaster University

MD Anderson Cancer Ctr

MD Anderson Cancer Ctr

MD Anderson Cancer Ctr

MD Anderson Cancer Ctr

Medigen Biotechnology Corp

MedImmune Ltd

Medivation Inc

Medivation Inc

Medivir AB

Medivir AB

Memorial Sloan Kettering Cancer Ctr

Memorial Sloan Kettering Cancer Ctr

Memorial Sloan Kettering Cancer Ctr

Memorial Sloan Kettering Cancer Ctr

Merck

Merck

Merck & Co

Merck & Co

Merck & Co

Merck & Co

Merck & Co

Merck & Co Inc

Merck & Co Inc

Merck & Co Inc

Merck & Co Inc

Merck Research Labs

Merck Research Labs

Merck Research Labs

Merck Research Labs

Metabolon Inc

Metabolon Inc

Metabolon Inc

Midwestern University

Millennium The Takeda Oncology Co

MilliporeSigma

MilliporeSigma

MilliporeSigma

MilliporeSigma

Miltenyi Biotec Inc

Miltenyi Biotec Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics

ModiQuest Research BV

Molecular Medicine Research Institute

Molecular Medicine Research Institute

Molecular Sensing Inc

Molecular Sensing Inc

Molecular Sensing Inc

MPM Capital LP

Multispan Inc

NantKwest Inc

Natl Health Research Institutes

Natl Research Council Canada

Natl Research Council Canada

Natl Taiwan University

Natl Taiwan University

Natl Taiwan University

NB Health Lab Co Ltd

Netherlands Cancer Institute

Netherlands Translational Research Ctr BV NTRC

Neurotech Pharmaceuticals

New York Medical College

New York University

New York University

NightstaRx Ltd

NightstaRx Ltd

NIH NCATS

NIH NCATS

NIH NCATS

NIH NCATS

NIH NCATS

NIH NCATS

NIH NCI

NIH NCI

NIH NCI

NIH NCI

NIH NHGRI

NIH NHGRI

NIH NHLBI

NIH NIAID

Nixon Peabody LLP

North Carolina State University

Northeastern University

Northwestern University

Northwestern University

Novan Inc

Novartis Institutes for Biomedical Research Inc

Novartis Institutes for BioMedical Research Inc

Novartis Institutes for BioMedical Research Inc

Novartis Institutes for BioMedical Research Inc

Novartis Institutes for BioMedical Research Inc

Novartis Institutes for BioMedical Research Inc

Novartis Institutes for BioMedical Research Inc

Novo Nordisk Research Ctr China

NTRC BV

Nuevolution AS

Oculis ehf

Ohio State University

Ohr Pharmaceutical Inc

Omeros Corp

Ono Pharma USA Inc

ONO Pharmaceutical Co Ltd

Ontario Institute for Cancer Research

OpenBiome

Ophthotech Corp

Ora Inc

Oryzon Genomics

Oslo University Hospital

Oslo University Hospital Radiumhospitalet

Palobiofarma SL

Partners Healthcare Innovation

Partners Healthcare System Inc

Paul Scherrer Institut

PerkinElmer Inc

Peter MacCallum Cancer Ctr

Pfizer Global R&D

Pfizer Global R&D

Pfizer Global R&D

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Inc

Pfizer Research Labs

Pfizer Research Labs

PharmOptima LLC

PharmOptima LLC

PIQUR Therapeutics AG

Prince of Wales Hospital

Progenra Inc

Promega Corp

Promega Corp

Promega Corp

Proteros Biostructures GmbH

Quanticel Pharmaceuticals

Queens University Of Belfast

RA Capital Mgmt LLC

RaNA Therapeutics Inc

RaNA Therapeutics Inc

Raze Therapeutics Inc

Raze Therapeutics Inc

Reaction Biology Corp

Reaction Biology Corp

Reaction Biology Corp

Reaction Biology Corp

Rebiotix Inc

Rebiotix Inc

Reckitt Benckiser

Recursion Pharmaceuticals

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Research Institute at Nationwide Childrens Hospital

ResVerlogix Corp

RetroSense Therapeutics LLC

Ribon Therapeutics

Rinat Pfizer

Roche Pharma

Rockefeller University

Rodin Therapeutics

Rutgers University

RXi Pharmaceuticals Corp

RXi Pharmaceuticals Corp

Salipro Biotech AB

Salk Institute for Biological Studies

Sanford Burnham Prebys Medical Discovery Institute

Sankyo Co Ltd

Sanofi Genzyme R&D Ctr

sanofi R&D

Santen Inc

Schepens Eye Research Institute

Schrodinger Inc

Schrodinger Inc

Schrodinger Inc

Scripps Research Institute

Scripps Research Institute

Scripps Research Institute

Selleck Chemicals LLC

Selleck Chemicals LLC

Selleck Chemicals LLC

Sentara Norfolk General Hospital

Servier Research Institute

Shanghai Jiao Tong University

Shanghai Tech University

Sigma Aldrich Israel Ltd

Simulations Plus Inc

Sorrento Therapeutics Inc

Sorrento Therapeutics Inc

St Jude Childrens Research Hospital

St Louis University

Stanford University

Stanford University

Stop ALD Foundation

Stowers Institute for Medical Research

Stowers Institute for Medical Research

Structural Genomics Consortium

Structural Genomics Consortium

Sun Pharma Advanced Research Ctr

SUNY Upstate Medical University

Symberix Inc

Symbiotic Health Inc

Syndax Pharmaceuticals Inc

Synthetic Biologics Inc

Taconic

Taiho Pharmaceutical Co Ltd

Takeda Cambridge Ltd

Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Technical University of Braunschweig

Tetragenetics Inc

Teva Pharmaceuticals

Texas Tech University

Texas Tech University

Theravance Biopharma US Inc

Thermo Fisher Scientific

Thermo Fisher Scientific

Thermo Fisher Scientific

Thermo Fisher Scientific

Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

Thomas Jefferson University

TNO Applied Scientific Research

Tokai Pharmaceuticals Inc

Toxikon Corp

Toxikon Corp

Toxikon Corp

Trillium Medical Ventures

Trillium Medical Ventures

Trillium Medical Ventures

Trillium Therapeutics Inc

TTP LabTech Inc

TTP LabTech Ltd

TTP LabTech Ltd

Tulane University

uBiome

UbiQ Bio BV

UCB Pharma

University Hospital Regensburg

University of California Berkeley

University of California Davis

University of California Los Angeles

University of California San Diego

University of California San Diego

University of California San Diego

University of California San Diego

University of California San Diego

University of California San Francisco

University of California San Francisco

University Of Chicago

University of Colorado Denver

University of Colorado Denver

University of Copenhagen

University of Dundee

University of Florida Gainesville

University of Gothenburg

University Of Illinois Chicago

University Of Illinois Chicago

University of Illinois Chicago

University of Illinois Chicago

University of Illinois Urbana

University Of Illinois Urbana Champaign

University Of Iowa

University of Iowa

University of Louisville

University Of Massachusetts

University of Massachusetts

University Of Massachusetts

University Of Massachusetts Lowell

University of Miami

University of Michigan

University of Michigan

University of Minho

University Of Minnesota Twin Cities

University of Minnesota Twin Cities

University Of Minnesota Twin Cities

University Of Missouri Columbia

University of Navarra

University Of Nebraska Omaha

University of North Carolina

University of North Carolina Chapel Hill

University of Nottingham

University of Oxford

University of Oxford

University of Oxford

University of Oxford

University of Oxford

University of Oxford

University Of Pennsylvania

University of Pennsylvania

University Of Pennsylvania

University of Pennsylvania

University of Rochester

University of South Carolina

University of Southern California

University of Texas Dallas

University of Texas Dallas

University of Texas San Antonio

University of Toronto

University of Toronto

University Of Zurich

University Of Zurich

Van Andel Research Institute

Van Andel Research Institute

Vanderbilt University

Vanderbilt University

Vanderbilt University

Vedanta Biosciences

Verastem Inc

Vertex Pharmaceuticals Canada Inc

Vertex Pharmaceuticals Canada Inc

Viamet Pharmaceuticals Inc

Virgina Commonwealth University

Visterra Inc

Visterra Inc

Vrije University Brussels

Walter & Eliza Hall Institute of Medical Research

Washington University

Whitehead Institute for Biomedical Research

Whitehead Institute for Biomedical Research

X Chem Pharmaceuticals Inc

X Chem Pharmaceuticals Inc

Yale University

Yale University

Yale University

Yale University

Yuhan Corp

Zebra Biologics Inc

ZoBio BV

Zoetis

Title

Sr Research Scientist

Head

Principal Research Scientist

Dir Medicinal Chemistry Technologies

Sr Leader & Head

Specialist

Sr Product Mgr

President & CEO & Dir

Assoc Dir of Discovery

Research Fellow

Assoc VP Biology

Scientist

Staff Scientist

Staff Scientist

VP Chemistry & Mfg

Key Account Mgr

Product Mgr & Gene Regulation Mgr

Sales Dir

CSO

Scientist I

VP Clinical Dev

CSO

Head

Head

Dir Molecular Biology

Sr Dir Metabolism

Assist Prof

Prof & Lecturer

VP & Site Head

Scientist II

Head

Product Mgr

Scientist

Sr Product Mgr

Dir

Principal Scientist

Principal Scientist

Principal Scientist & Grp Leader

Scientist

CEO

Asst Prof

President

CMO

Bus Dev Dir

CSO

Key Acct Mgr

Assoc Research Prof

CEO

Researcher

President & CEO & CSO

Sr Dir of Translational Dev

Research Fellow

Researcher

VP & Head

Principal Biomedical Informatics Scientist

Dir Strategy & Externalization

Exec Dir & Head

Principal Scientist & Team Leader

Team Leader

PostDoc

Entrepreneur In Residence

Entrepreneur In Residence

Commercial Mgr

Sr Mgr

Founder & CSO

Dir Research

Scientist I

Research Scientist

Assoc Prof

Asst Prof Translational Nanomedicine Research Lab

Sr Scientist

Dir Marketing

Mgr

President

R&D

Sr Application Scientist

Prof

CEO

Sr Research Assoc

Assoc Dir and Head

Assoc Dir Program Mgmt

Dir Discovery Proteomics

Scientist I

Scientist II

Sr Assoc Scientist III

Sr Scientist

Scientist

Venture Partner

Field Application Scientist

VP Sales

GM

Dir

Lab Head

Dir Research Beyond Borders

Sr Principal Scientist

Lab Manager

Scientist II

President & CEO

Asst Prof

Dir

Dir

Visiting PostDoc Fellow

Sr Principal Scientist & Grp Leader

Sr Research Investigator II

Assoc Dir

Principal Investigator & Dir

Project Mgr

Chief Dev Officer

CSO

Dir Cell Pharmacology

Research Scientist I

Dir Biology

Dir

Dir CS

Sr Mgr

Sr Mgr

Bus Dev Mgr

CSO

Mgr Pharmaceuticals Sales & Bus Dev

CSO

Sr Scientist

Sr Dir R&D

Dir

Executive Dir

Senior Principal Scientist

President & CSO

Dir Marketing & Bus Dev

Dir Operations

Lead Research Scientist

Sr Product Mgr

VP New Ventures

Exec Officer

VP Sales & Marketing

Client & Scientific Portfolio Mgr

Exec Dir Sales & Marketing

Prof & Chief

Medical Technologist

Researcher

Scientist

Head

Mfg Dir

CSO

Research Fellow

Scientist

Customer Success Consultant

Dir

Dir Customer Engagement

President & CEO

Co Founder & Head

VP

VP Research

Head

CEO

VP Research

Assoc Specialist

Managing Dir

Head

CSO & Founder

Sr Scientist

Research Dir Biology

Dir Scientific Affairs

CSO

Researcher

Sr Researcher

Sr Researcher

Asst Prof

Principal Research Assoc

Principal Scientist

Research Assoc

PhD Candidate

Northeast Sales Representative

Chief Diagnostics & Detection & Threat Surveillanc

Founder & Chief Consultant

VP Research

Dir Genomics Svcs

North East Account Mgr

SVP

CSO

CEO

Dir

Mgr

Product Sales Specialist

Regional Mgr

Sr Product Mgr

Sr VP Commercial Operations

VP & Site Head

Dir Bus Dev

Dir Customer Strategy & Dev

CEO & Chief Growth Officer

Prof

Prof & Dir Ctr for Virology

Asst Prof

Grp Leader & Sr Research Advisor

Sr Research Advisor

Co Founder & CEO

Assoc Dir

Dir In Vivo Pharmacology

Sr Scientist

Prof & Georgia Eminent Scholar

Sr Scientist

CTO

Dir Markets & Application Dev

Dir Scientific Sales

Assoc Dir Lead Discovery

Exec Dir Lead Discovery

Sr Assoc Scientist

Sr Scientist

Sr Scientist

VP

Head

Sr VP Intellectual Property

Exec VP Corp Strategy & Bus Dev

CEO

Mgr

CMO

Principal Scientist

CSO

Exec Dir Reprogramming Biology

President & CFO

Toxicologist

Scientist

Dir

Dir Medicinal Chemistry

Scientist

Sr Dir Immunology

Sr Principal Scientist

Asst Prof

Prof & Head

Dir

Assoc Scientist

Sr Product Mgr

Sr Scientist

Grp Lead

Principal Scientific Researcher

Scientific Mgr

Scientist

Sr Scientific Researcher

Sr Scientist

Sr Scientist & Project Team Leader

CEO & Founder

Marketing Liaison

Asst Prof

Prof

Prof Hematology & Oncology & Dir

Principal Investigator

Chair

Dir

Dir Computational Biology

Dir Medicinal Chemistry

Investigator

Investigator

Investigator

Mgr

Principal Scientist

Scientist

Dir of Life Sciences & Grp Leader

Grp Leader

Mgr

CEO

VP Dir

Alliance Manager

Tech Consultant

Asst Dir

Asst Prof

Data Analyst

Lecturer

Prof

Research Fellow

Research Fellow in Genetics

Sr Bioinformatician

Erving Prof of Chemistry

Grp Leader

Consultant

Prof

COO

VP Mfg

Bioinformatician

CEO

CSO

Asst Prof

Sr Scientist

Sr Lecturer

Assoc Dir Applied Technology

Principal Scientist

President

Researcher

Full Prof

Research Scientist

Dir

VP R&D

VP Sales & Customer Relations

Principal

VP General Medicine & Scientific Affairs

VP Product Dev

Head Scientific Innovation

Sr Scientist

Assoc Scientific Dir

Head

Principal Scientist

Assoc Dir Research Bus Dev

VP

Prof

Prof Ophthalmology

Principal Scientist

Sr Research Scientist

Prof

Sr Dir Chemistry

CSO

VP Research & Translational Dev

Dir Medicinal Chemistry

Resident

Researcher

Sr Research Scientist

Researcher

Researcher

Sr Account Exec

Prof & Chairman

CEO & President

Grp Leader

Dir & Founder

Sr Editor

VP Science & Tech Hub

Dir Bus Dev

Mgr Marketing & Sales

Dir Stem Cells

Market Dev Mgr

Principal Scientist

Founder & CEO

Asst Prof

Assoc Prof

Assoc Prof

Asst Prof

Assoc Prof

Assoc Prof

Graduate Student Harvard Biophysics Program

Research Scientist

Student

Sr Lecturer

Chair

Prof

Assoc Prof

Assoc Scientist IV

Asst Prof

Researcher

CSO

Sr Scientist

Dir Bioassay

VP Pharmaceutical Tech Operations

Dir Biology

Sr Scientist & Team Leader

Assoc Member & Assoc Prof

Asst Attending Physician

Head

Research Fellow

Assoc Principal Scientist

Assoc Scientist

Assoc Principal Investigator

Dir Cellular Pharmacology

Dir Medicinal Chemistry

Scientist

Sr Scientist

Assoc Prinicipal Scientist

Exec Dir

Research Fellow

Sr Scientist

Assoc Principal Scientist

Dir Exploratory Chemistry

Dir Research

Sr Scientist

Bus Dev Exec

CSO

Head Global Bus Dev

Assoc Prof

Dir Biochemistry

Global Market Segment Mgr

Global Product Mgr

Product Mgr

Scientist

Clinical Applications Mgr

Clinical Instrument Specialist

Sr Research Scientist

Sr Research Assoc

President & CEO

Dir Cell Biology & Head

Exec Dir & Sr Scientist

CEO

Lab Supv & Scientist

Sr VP R&D

Managing Dir & Chief IP Counsel

Business Development Consultant

VP R&D

Distinguished Investigator

Research Officer

Team Leader

PostDoc

PostDoc Fellow

Prof

President

Head

Managing Dir & Head

VP Core Technology Dev

Asst Prof

Core Faculty Member NY Genome Ctr & Asst Prof

Dir

CEO

CSO

Branch Chief

Chemistry Grp Leader

Grp Leader

Head

Research Scientist

Team Leader

Principal Investigator

Research Scientist

Scientific Review Officer

Staff Scientist

Projector Coordinator

Sr Investigator

Research Assoc

Biochemist & Molecular Biologist

Patent Specialist

PhD Candidate

Asst Prof

Asst Prof

PostDoc

CMO

Chemist

Investigator II

Research Investigator

Scientist

Sr Investigator

Sr Investigator I

Sr Investigator I

Sr Scientist

Sales Mgr

Research Scientist & Project Mgr

CEO

Assoc Prof

CEO

Sr Dir Research

Sr Mgr

Dir Medicinal Chemistry

Research Scientist

CMO

VP Clinical Strategy

Sr VP Corp Dev

CSO & Co Founder

Researcher

Prof

CEO

Sr Mgr

Dir

Head

Global Product Leader

Prof

Assoc Research Fellow

Assoc Research Fellow

Head Rare Diseases Chemistry

Assoc Research Fellow

Dir Epigenetics

Head

Head Functional Genomics & Biolomics

Principal Scientist

Sr Dir BioMedicine Design

Sr Dir Medicinal Chemistry

Sr Principal Scientist

Sr Scientist

Sr Scientist

Sr Scientist

Exec Dir External R&D Innovation

Principal Scientist

Dir Assay Dev

VP

CSO

Assoc Prof

President & CEO

Sr Product Mgr

Sr Research Scientist

Sr Research Scientist

Bus Dev

Dir

Researcher

Assoc

Sr Scientist

VP

Head

Sr Dir & Head Drug Discovery

Dir Epigenetics

Dir Strategic Partnerships

Research Scientist

Sr Scientist

Dir R&D

VP Tech Operations & Bus Dev

Associate

Co Founder & CEO

Dir R&D Chemistry

Dir Therapeutic Proteins

Research Assoc

Scientist

Scientist

Sr Staff Scientist

Prof

CSO & Co Founder

CEO

Scientist

Assoc Research Fellow

PostDoc

PostDoc Fellow

Sr Dir CNS Research

Scientist

Chief Dev Officer

Mgr

Founder & CEO

PostDoc Research Assoc

Dir Medicinal Chemistry

Assoc Sr Researcher

Sr Scientific Dir Gene Therapy & Ophthalmology

Project Leader

Exec Dir & Head

Postdoc Fellow

Acct Mgr

Acct Mgr

Sr Principal Scientist

Assoc Scientific Dir & Asst Prof

Prof

Sr Scientist

Engineer

Engineer

Sales Engineer

Assoc Dir Translational Research

Research Scientist

PostDoc

Assoc Investigator

Dir

Principal Scientist

Dir Experimental Cellular Therapy

Dir Research

Assoc Faculty Member

Research Prof

Assoc Prof Computer Science

PostDoc Research Assoc

CSO

Head

Lab Mgr II

Grp Leader

PostDoc Fellow

Assoc VP

Prof

President & CEO

Founder & CEO

CTO & Co Founder

VP Clinical & Regulatory Affairs

Sr Product Mgr

Researcher

Principal Scientist

Mgr

Researcher

Grp Leader Institute for Biochemistry

Dir

Scientist

Asst Prof

Prof of Biomedical Sciences & Co Dir

Research Assoc

Global Dir

Product Mgr

Sr Mgr

Sr Mgr

Assoc Dir

Global Commercial Dir Cell Biology

Prof & Chair

Research Scientist

Dir

Bus Dev Mgr

Study Dir

Study Dir

Managing Partner

Partner

Technology Analyst

Research Scientist

US Field Applications Scientist

Regional Sales Mgr

Sr Commerical Scientist

Prof & Chair

Research & Collaborations Lead

CSO & COO

Research Scientist

Graduate Student

Prof

Prof

Dir

Assoc Adjunct Prof

Assoc Prof

Prof

Prof Ophthalmology

Project Scientist

Prof

Prof

Prof

Assoc Prof & Assoc Head Translational Research

Prof

Assoc Prof

Assoc Prof

Prof & Assoc Chair

Prof

Distinguished Prof

Post Doc Research

Prof Emeritus

Prof Molecular Neuroscience

Head Pharmacology & Prof

Phillip A Sharp Prof

Assoc Prof of Pediatrics

Asst Prof

Prof Ophthalmology & Visual Sciences

Assoc Prof

PostDoctoral Fellow

Prof

Prof Computer Science & Dir

Assoc Dean & Prof & Dir

Prof Emeritus

Warner Lambert Parke Davis Prof Medicine

Assoc Prof

Prof

Prof

Prof Hematology & Oncology

Asst Research Prof

Dir

Assoc Prof

William Rand Kenan Jr Prof

Research Asst Prof

Prof

PostDoc Research Assoc

Principal Investigator

Prof

Prof

Prof

Prof & Chair

Assoc Prof

Asst Prof

Graduate Student

Prof

Prof

Assoc Prof Medicinal Chemistry

PostDoctoral Fellow

Asst Prof

Chair Obesity & Diabetes & Prof

Asst Prof Molecular Medicine

Asst Prof

Principal Investigator

Graduate Student

Postdoctoral Fellow

Distinguished Scientific Investigator & Head

Head

Drug Discovery Scientist

Prof

Research Asst Prof

Co Founder & CEO

Clinical Science Mgr

Assoc Dir

Dir Biology

Dir Medicinal Chemistry

Graduate Student

Exec Dir Research

Principal Scientist

Prof

Lab Head

Carl Cori Prof Cell Biology & Physiology & Dir

Postdoctoral Researcher

Research Scientist & Mgr

Sr Scientist

Sr VP Research

Asst Prof

Dir

Graduate Student Chemistry

Lewis B Cullman Prof Molecular Cell & Dev Biology

Chief Scientific Officer

CSO & Head R&D

CEO

Sr Scientist

SOURCE

From: CHI Conferences <bethanyg@healthtech.com>

Date: Monday, August 15, 2016 at 2:12 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: See Who’s Attending Discovery on Target; Deadline to Save Extended

Read Full Post »

CHI’s NK Cell-Based Cancer Immunotherapy Symposium, September 19 in Boston

Reporter: Aviva Lev-Ari, PhD, RN

 

Announcement from LPBI Group: key code LPBI16 for Exclusive Discount to attend Boston’s Discovery on Target (September 2016)

Announcement from LPBI Group: key code LPBI16 for Exclusive Discount to attend Boston’s Discovery on Target (September 2016)

DOT-150x150

DOT-NCT-700x150

FEATURED SESSION:

Natural killer (NK) cells have been known to have advantages over T cells, yet their therapeutic potential in the clinic has been largely unexplored.

Cambridge Healthtech Institute’s NK Cell-Based Cancer Immunotherapy Symposium, September 19 in Boston, is dedicated to the exploration of utilizing NK cells for new adoptive cell therapies, including updates from ongoing clinical studies.

NK CELL IMMUNO-ONCOLOGY AND CLINICAL STUDIES

Harnessing Adaptive NK Cells in Cancer Therapy

Karl-Johan Malmberg, M.D., Ph.D., Professor, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital

  • We have recently completed a Phase I/II clinical trial with transfer of haploidentical NK cells to patients with high-risk myelodysplastic syndrome. Six of the 16 treated patients achieved morphological complete remission and five of these underwent allogeneic stem cell transplantation resulting in long-term survival in four patients. The quality and number of infused NK cells as well as their transient engraftment in the recipient correlated with decrease in mutational burden and clinical outcomes. These results suggest that adoptive transfer of allogeneic NK cells may hold utility as a bridge to transplant in patients who are refractory to induction therapy. Current efforts to selectively expand metabolically optimized adaptive NK cells for the next generation NK cell cancer immunotherapy will be discussed.

Update on Systemic and Locoregional Cancer Immunotherapy with IL-21-Expanded NK Cells

Dean Anthony Lee, M.D., Ph.D., Professor, Pediatrics; Director, Cellular Therapy and Cancer Immunotherapy Program, Nationwide Children’s Hospital; James Comprehensive Cancer Center/Solove Research Institute, The Ohio State University

  • The ability to generate clinical-grade NK cell products of sufficient purity, number, and function has enabled broader application of adoptive NK cell therapy in clinical trials. We translated our IL-21-based NK cell expansion platform to clinical grade and scale and initiated 7 clinical trials that administer NK cell immunotherapy with high cell doses or repeated dosing in transplant, adjuvant, or stand-alone settings. These trials have collectively delivered approximately 150 infusions to over 60 patients at doses of up to 10e8/kg. We will discuss the importance of STAT3 signaling in this setting, describe early outcome and correlative data from these studies, and present preclinical data supporting future clinical trials that build on this platform.

REGISTER

BY AUGUST 12 TO

SAVE UP TO $200

VISIT

WEBSITE

DOWNLOAD PDF AGENDA

Suggested Event Package

SYMPOSIUM

NK Cell-Based Cancer Immunotherapy

SEPT. 19

CONFERENCE

Antibodies Against Membrane Protein Targets (Part One)

SEPT. 20-21

CONFERENCE

Antibodies Against Membrane Protein Targets (Part Two)

SEPT. 21-22

The exhibit hall was sold out in 2015, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2016, contact:

Jon Stroup

Sr. Business Development Manager

P: 781-972-5483

E: jstroup@healthtech.com

Sponsorship/Exhibitor Information >>

 

DiscoveryOnTarget.com | Register by August 12 to SAVE up to $200 | Download PDF Agenda

Cambridge Healthtech Institute | 250 First Avenue, Suite 300, Needham, MA 02494 | www.healthtech.com | 781-972-5400

SOURCE

From: NK Cell Symposium <heidio@healthtech.com>

Date: Tuesday, August 9, 2016 at 1:40 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: NK Cells for Adoptive Therapies: The Future of Cancer Immunotherapy?

Read Full Post »

Advances in Gene Editing and Gene Silencing | September 20-21, 2016 | Boston, MA

Reporter: Aviva Lev-Ari, PhD, RN

2.1.5.28

2.1.5.28   Advances in Gene Editing and Gene Silencing | September 20-21, 2016 | Boston, MA, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Kinase Inhibitor Discovery September 21-22, 2016 Boston

KEYNOTE SESSION: GENOME EDITING FOR IN VIVO APPLICATIONS

Part 1 (of a two-part conference) will cover the use of CRISPR/Cas9 and RNAi for identifying new drug targets and therapies. It will bring together experts from all aspects of basic science and clinical research to talk about how and where gene editing and RNAi can be best applied. What are the different tools that can be used and what are their strengths and limitations? How does the CRISPR/Cas system compare to RNAi and other gene editing tools, such as Transcription Activator-like Effector Nucleases (TALENs) and zinc finger nucleases (ZFNs), and do they have any complementary uses? Scientists and clinicians from pharma/biotech as well as from academic and government labs will share their experiences leveraging the utility of gene editing for target discovery, disease modeling, and for creating cell and viral therapies. Learn more atDiscoveryOnTarget.com/RNAi-screens-functional-genomics

Advance Registration Discount Available!
Register by August 12 Week to Save up to $200

Keynote Session: Genome Editing for In Vivo Applications

AAV for Gene Therapy and Genome Editing
James Wilson, M.D., Ph.D., Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine; Director, Orphan Disease Center and Director, Gene Therapy Program, University of Pennsylvania
In vivo delivery of nucleic acid therapeutics remains the primary barrier to success. My lab has focused on the use of vectors based on adeno-associated virus (AAV) for achieving success in pre-clinical and clinical applications of gene replacement therapy. Most of the current academic and commercial applications of in vivo gene replacement therapy are based on endogenous AAVs we discovered as latent viral genomes in primates. These vectors are reasonably safe and efficient for application of gene replacement therapy. The emergence of genome editing methods has suggested more precise and effective methods to treat inherited diseases in which genes are silenced or mutations are corrected. AAV vectors have been the most efficient platform for achieving genome editing in vivo. We will review our attempts to achieve therapeutic genome editing in animal models of liver disease using AAV.

Using CRISPR/Cas to Target and Destroy Viral DNA Genomes
Bryan R. Cullen, Ph.D., James B. Duke Professor of Molecular Genetics and Microbiology and Director, Center for Virology, Duke University
A number of pathogenic human DNA viruses, including HBV, HIV-1 and HSV1, cause chronic diseases in humans that remain refractory to cure, though these diseases can be controlled by antivirals. In addition the DNA virus HPV causes tumors that depend on the continued expression of viral genes. Here, I will present data demonstrating that several of these viruses can be efficiently cleaved and destroyed using viral vectors that express Cas9 and virus-specific guide RNAs, thus providing a potential novel approach to treatment.

Targeted Endonucleases as Antiviral Agents: Promises and Pitfalls
Keith R. Jerome, M.D., Ph.D., Member, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Professor and Head, Virology Division, Department of Laboratory Medicine, University of Washington
Genome editing offers the prospect of cure for infections such as HIV, hepatitis B virus, herpes simplex, and human papillomavirus, by disruption of essential viral nucleic acids or the human genes encoding receptors needed for viral entry. This talk will highlight the most recent laboratory data and the challenges still ahead in bringing this technology to the clinic.

Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing
Daniel Anderson, Ph.D., Professor, Department of Chemical Engineering, Institute for Medical Engineering & Science, Harvard-MIT Division of Health Sciences & Technology and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
High throughput, combinatorial approaches have revolutionized small molecule drug discovery. Here we describe our high throughput methods for developing and characterizing RNA delivery and gene editing systems. Libraries of degradable polymers and lipid-like materials have been synthesized, formulated and screened for their ability to deliver RNA, both in vitro and in vivo. A number of delivery formulations have been developed with in vivo efficacy, and show potential applications for the treatment of genetic diseases, viral infections and cancers.

PANEL DISCUSSION: CRISPR/Cas: A Realistic and Practical Look at What the Future Could Hold
Moderator: Bryan R. Cullen, Ph.D., James B. Duke Professor of Molecular Genetics and Microbiology and Director, Center for Virology, Duke University
Participants: Session Speakers
Each speaker will spend a few minutes sharing their viewpoints and experiences on where things stand with using the CRISPR/Cas system for in vivo applications. Attendees will have an opportunity to ask questions and share their opinions.

About the Conference

Cambridge Healthtech Institute’s 13th annual two-part conference on Advances in Gene Editing and Gene Silencing will cover the latest in the use of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9-based gene editing and RNA interference (RNAi) for use in drug discovery and for developing novel drug therapies.


For sponsorship and exhibit sales information including podium presentation opportunities, contact:
Jon Stroup | T: +1 781-972-5483 | E: jstroup@healthtech.com


Recommended All Access Package:
Includes access to 1 Symposium and 2 Conferences

September 19 Symposium: 
Understanding CRISPR: Mechanisms and Applications

September 20-21 Conference:
Advances in Gene Editing and Gene Silencing – Part 1

September 21-22 Conference: 
Advances in Gene Editing and Gene Silencing – Part 2


Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA, USA

Tel: 781-972-5400 | Fax: 781-972-5425 | www.healthtech.com
This email is being sent to sjwilliamspa@comcast.net for marketing purposes. If it is not of interest to you, please disregard and we apologize for any inconvenience this may have caused.

Read Full Post »

The Roles of Graduate Students and Postdocs in the Emergence of Gene Editing: CRISPR Science and Technology

Curator: Aviva Lev-Ari, PhD, RN

2.1.5.13

2.1.5.13   The Roles of Graduate Students and Postdocs in the Emergence of Gene Editing: CRISPR Science and Technology, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

PLAN TO ATTEND

DOT-150x150

Understanding CRISPR: Mechanisms and Applications: CHI, September 19-22, 2016, Westin Boston Waterfront, Boston

https://pharmaceuticalintelligence.com/2016/04/06/understanding-crispr-mechanisms-and-applications-chi-september-19-22-2016-westin-boston-waterfront-boston/

Announcement from LPBI Group: key code LPBI16 for Exclusive Discount to attend Boston’s Discovery on Target (September 19-22, 2016, CRISPR: Mechanisms to Applications on 9/19/2016)

https://pharmaceuticalintelligence.com/2016/05/13/announcement-from-lpbi-group-key-code-lpbi16-for-exclusive-discount-to-attend-bostons-discovery-on-target-september-2016/

The emergence of Gene Editing: CRISPR Science and Technology provide evidence that since the NIH effort to sequence the Genome, this endeavor is the second one to follow as an evolving scientific community ecosystem at their best in COMPETITION AND COLLABORATION, as well as in the survival of the fittest struggle that yielded a legal battle on appropriation of the discovery and the rights to its Intellectual Property (IP).

On our Journal we published

70 articles on Gene Editing: CRISPR Science and Technology

See references in

UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The Biotech Patent Fight of the Century: UC, Berkeley and Broad Institute @MIT

UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The Biotech Patent Fight of the Century

Reporter: Aviva Lev-Ari, PhD, RN

The unsung heroes of CRISPR

The soaring popularity of gene editing has made celebrities of the principal investigators who pioneered the field — but their graduate students and postdocs are often overlooked.

20 July 2016
Nature 535,342–344(21 July 2016)doi:10.1038/535342a
Heidi writes and Wiedenheft is quoted:
Doudna and other principal investigators involved in the seminal work have become scientific celebrities: they are profiled in major newspapers, star in documentaries and are rumoured to be contenders for a Nobel prize. “When I came to the lab, I was the only person studying CRISPR,” Wiedenheft says. “When I left the lab, almost everyone was studying it.”

His work with Doudna yielded a First author place on their 2011 Nature article:

Wiedenheft, B. et al. Nature 477, 486489 (2011).

In January 2016, Eric Lander, president of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, tossed into this minefield a historical portrait called ‘The Heroes of CRISPR

Lander, E. S. Cell 164, 1828 (2016).

Perspective

The Heroes of CRISPR

Eric S. Landercorrespondence

Editor of Cell received letters questioning the decision to publish Eric Lander’s article due to Broad Institute involvement in a legal dispute and presenting an incomplete picture of the evolution of the discovery and using a title that assigns the Heroism on a matter legally unsettled.

Does the Cell, 2016 article present all attributions due to:

1.The quiet revolutionary: How the co-discovery of CRISPR explosively changed Emmanuelle Charpentier’s life

The microbiologist spent years moving labs and relishing solitude. Then her work on gene-editing thrust her into the scientific spotlight.

27 April 2016

http://www.nature.com/news/the-quiet-revolutionary-how-the-co-discovery-of-crispr-explosively-changed-emmanuelle-charpentier-s-life-1.19814

and

2. Bitter fight over CRISPR patent heats up

Unusual battle among academic institutions holds key to gene-editing tool’s future use.

12 January 2016
Prof. Doudna at UC, Berkeley and Prof. Church at Harvard, both support appropriate credit to students involved in the discovery, yet the reality is that the
credit in science goes to the Leader of the lab, as do any prizes that follow.

BioTech Industry Prospect for Student of Powerhouse Academic Labs: Alternative Careers to Academic Positions

Read Full Post »

Thriving Three Groups on LinkedIn

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #206: Thriving Three Groups on LinkedIn. Published on 7/20/2016

WordCloud Image Produced by Adam Tubman

Groups Launcher and Group Manager: Aviva Lev-Ari, PhD, RN

Cardiovascular Biotech & Pharma UK & US Networking Group

954 members

https://www.linkedin.com/groups/4357927

Leaders in Pharmaceutical Business Intelligence

350 members

https://www.linkedin.com/groups/4346921

Innovation in Israel

205 members

https://www.linkedin.com/groups/2987122

Read Full Post »

Lysyl Oxidase (LOX) gene missense mutation causes Thoracic Aortic Aneurysm and Dissection (TAAD) in Humans because of inadequate cross-linking of collagen and elastin in the aortic wall

Mutation carriers may be predisposed to vascular diseases because of weakened vessel walls under stress conditions.

Reporter: Aviva Lev-Ari, PhD, RN

2.1.3.7

2.1.3.7   Lysyl Oxidase (LOX) gene missense mutation causes Thoracic Aortic Aneurysm and Dissection (TAAD) in Humans because of inadequate cross-linking of collagen and elastin in the aortic wall – Mutation carriers may be predisposed to vascular diseases because of weakened vessel walls under stress conditions, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans

  1. Vivian S. Leea,
  2. Carmen M. Halabia,b,
  3. Erin P. Hoffmanc,1,
  4. Nikkola Carmichaelc,d,
  5. Ignaty Leshchinerc,d,
  6. Christine G. Liand,e,
  7. Andrew J. Bierhalsf,
  8. Dana Vuzmanc,d,
  9. Brigham Genomic Medicine2,
  10. Robert P. Mechama,
  11. Natasha Y. Frankc,d,g,3, and
  12. Nathan O. Stitzielh,i,j,3

Edited by J. G. Seidman, Harvard Medical School, Boston, MA, and approved June 7, 2016 (received for review January 27, 2016)

  • Author contributions: V.S.L., R.P.M., N.Y.F., and N.O.S. designed research; V.S.L., C.M.H., and N.O.S. performed research; E.P.H., N.C., C.G.L., D.V., B.G.M.P., R.P.M., and N.Y.F. contributed new reagents/analytic tools; V.S.L., C.M.

Significance

The mechanical integrity of the arterial wall is dependent on a properly structured ECM. Elastin and collagen are key structural components of the ECM, contributing to the stability and elasticity of normal arteries. Lysyl oxidase (LOX) normally cross-links collagen and elastin molecules in the process of forming proper collagen fibers and elastic lamellae. Here, using whole-genome sequencing in humans and genome engineering in mice, we show that a missense mutation in LOX causes aortic aneurysm and dissection because of insufficient elastin and collagen cross-linking in the aortic wall. These findings confirm mutations in LOX as a cause of aortic disease in humans and identify LOX as a diagnostic and potentially therapeutic target.

Abstract

Thoracic aortic aneurysms and dissections (TAAD) represent a substantial cause of morbidity and mortality worldwide. Many individuals presenting with an inherited form of TAAD do not have causal mutations in the set of genes known to underlie disease. Using whole-genome sequencing in two first cousins with TAAD, we identified a missense mutation in the lysyl oxidase (LOX) gene (c.893T > G encoding p.Met298Arg) that cosegregated with disease in the family. Using clustered regularly interspaced short palindromic repeats (CRISPR)/clustered regularly interspaced short palindromic repeats-associated protein-9 nuclease (Cas9) genome engineering tools, we introduced the human mutation into the homologous position in the mouse genome, creating mice that were heterozygous and homozygous for the human allele. Mutant mice that were heterozygous for the human allele displayed disorganized ultrastructural properties of the aortic wall characterized by fragmented elastic lamellae, whereas mice homozygous for the human allele died shortly after parturition from ascending aortic aneurysm and spontaneous hemorrhage. These data suggest that a missense mutation in LOX is associated with aortic disease in humans, likely through insufficient cross-linking of elastin and collagen in the aortic wall. Mutation carriers may be predisposed to vascular diseases because of weakened vessel walls under stress conditions. LOX sequencing for clinical TAAD may identify additional mutation carriers in the future. Additional studies using our mouse model of LOX-associated TAAD have the potential to clarify the mechanism of disease and identify novel therapeutics specific to this genetic cause.

SOURCE

http://www.pnas.org/content/early/2016/07/15/1601442113.abstract

Missense LOX Mutation Linked to Aortic Rupture, Aneurysm

NEW YORK (GenomeWeb) – Researchers from Washington University School of Medicine have linked a LOX gene variant with aortic rupture and aneurysm.

As they reported in the online early edition of the Proceedings of the National Academy of Sciences yesterday, the researchers sequenced two first cousins from a family with a history of aortic ruptures and aneurysms to uncover a missense mutation in the lysyl oxidase (LOX) gene, which encodes a protein that cross-links elastin and collagen. When they used CRISPR/Cas9 genome engineering to introduce the mutation into a mouse model, mice heterogeneous for the mutation had disorganized aortic walls, while mice homozygous for the mutation died shortly after birth of ascending aneurysm and spontaneous hemorrhage, suggesting that the LOX variant might be causal.

Read more @ the Source

SOURCE

https://www.genomeweb.com/sequencing/missense-lox-mutation-linked-aortic-rupture-aneurysm

Read Full Post »

A Conversation with Jennifer Doudna, Interviewer: Jan Witkowski, Executive Director, Banbury Center at Cold Spring Harbor Laboratory

Reporter: Aviva Lev-Ari, PhD, RN

2.1.5.14

2.1.5.14   A Conversation with Jennifer Doudna, Interviewer: Jan Witkowski, Executive Director, Banbury Center at Cold Spring Harbor Laboratory, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

A Conversation with Jennifer Doudna

INTERVIEWER: JAN WITKOWSKI Executive Director, Banbury Center at Cold Spring Harbor Laboratory

Jennifer Doudna is a Professor in the Department of Chemistry and the Department of Molecular and Cell Biology at the University of California –Berkeley.

Jan Witkowski: People know of you primarily through your work on the CRISPR –Cas9 system for genetic engineering. Can you go over the biology of the system and how you got involved in working on it?

Dr. Doudna: We started working on CRISPR (clustered regularly interspaced short palindromic repeats) biology about 10 years ago. A colleague of mine at Berkeley, Jillian Banfield, was doing research on bacterial comJmunities and the viruses that infect them. She had noticed a lot of repetitive sequences in their genomic data and wondered if these were being used in the form of RNA molecules to protect the bacteria from viral infection. This led to our work with Emmanuelle Charpentier to understand the function of a particular protein called Cas9 (CRISPRassociated protein 9), which turns out to be an RNAguided DNA cutting enzyme. This is a great way for bacteria to fight viruses. It’s an adaptive immune system. The bacteria acquire genetic material from viruses and insert them into these CRISPR sequences. They can transcribe the stored sequence into RNA, and then those RNA molecules can base-pair the matching viral DNAs sequences. They use RNA molecules to target the viral sequences and Cas9 cuts the viral DNA. About half of the sequenced bacterial genomes have one or more CRISPR loci in the genome. Jan

Witkowski: Why is it not more widespread?

Dr. Doudna: Bacteria have a lot of ways to avoid viruses. CRISPR systems operate in certain kinds of bacteria, perhaps in certain environments where they’re particularly advantageous. Other bacteria simply might not need them because they have other ways of fighting the viruses they encounter.

Jan Witkowski: Bacteria have different enzymes depending on the type of CRISPR system, but Cas9 is the one that caught people’s attention for genome engineering. Why is that particularly useful?

Dr. Doudna: It’s programmable. It can be targeting using a short sequence of RNA that provides the base-pairing information to recognize DNA molecules with a matching or complementary sequence. Cas9 is also useful because the enzyme cuts both strands of double-stranded DNA. 

READ more @SOURCE

SOURCE

http://www.cshlpress.com/pdf/sample/2016/symp80/Symp80_Doudna.pdf?utm_source=Email&utm_medium=email&utm_content=DoudnaConversation&utm_campaign=July2016Email2

Read Full Post »

Women Leaders in Cell and Gene Therapy

Reporter: Aviva Lev-Ari, PhD, RN

2.1.5.15

2.1.5.15   Women Leaders in Cell and Gene Therapy, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Before we review the content, below – We suggest to nominate for inclusion in this list, Prof. Jeniffer Doudna of University of California, Berkeley who started THREE start ups on Gene Editing.

Pioneering names in CRISPR are Jeniffer Doudna and Emmanuelle Charpentier, both names are not mentioned in the ‘The Most Influential Women in Cell & Gene Therapy’ as is described in the names of 15 Women Leaders in Cell and Gene Therapy, below.

About Jeniffer Doudna contributions to Gene Editing, Read:

UPDATED – Medical Interpretation of the Genomics Frontier – CRISPR – Cas9:  Gene Editing Technology for New Therapeutics

Authors and Curators: Larry H Bernstein, MD, FCAP and Stephen J Williams, PhD and Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2015/09/07/medical-interpretation-of-the-genomics-frontier-crispr-cas9-gene-editing-technology-for-new-therapeutics/

Read also

UPDATED – Status “Interference — Initial memorandum” – CRISPR/Cas9 – The Biotech Patent Fight of the Century: UC, Berkeley and Broad Institute @MIT

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/01/06/status-interference-initial-memorandum-crisprcas9-the-biotech-patent-fight-of-the-century/

Women in Cell & Gene Therapy

When considering the hurdles to commercialisation, one of our partners described his situation as, ‘It’s no longer the science or investment, it’s the people.’ 

This month, the National Cell Manufacturing Consortium released their roadmap to 2025 and of the 5 key areas of focus mentioned in the white paper, workforce development is arguably the most pressing.

“Today’s hurdle in #celltherapy commercialization: ‘It’s no longer the science or investment, it’s the people.’ @phacilitate #STEM”

Full scale cell & gene therapy industrialisation is so close we can smell it.

The sector is buzzing with innovation, sound business structure and plenty of interest from external stakeholders. From our perspective, it’s absolutely fascinating to watch.

Medicine as we know it, is about to change dramatically. Major cell & gene therapy treatments will become the mainstay of doctor’s surgeries and hospitals. Healthcare leaders will be forced to consider a diverse portfolio of treatments for unmet medical needs.

DOWNLOAD 15 INFLUENTIAL WOMEN IN CELL AND GENE THERAPY  eBOOK

But we have a problem. With a quick search on LinkedIn you’ll see that some of the major cell therapy developers are bolstering their workforce. Juno have advertised over 30 new roles in 10 days, GSK, Mesoblast and Pfizer are also recruiting for a wide range of science-based roles. A ball-park count shows there could be over 1000 industrial cell & gene therapy roles being advertised while you read this.

Research has shown time and again that diversity makes great business sense. Best-selling author Daniel Goleman advocates, the traits for successful leadership are knowledge and emotional intelligence, characteristics that transcend gender lines. Yet women continue to make up just 4% of leadership roles. The disparity was a hot subject of conversation at Davos this year and solutions are being discussed to attract talented females to this exciting and growing STEM industry.

SIGN-UP FOR EMAIL UPDATES

When we think of female science leaders, historical figures like Marie Curie and Rosalind Franklin tend to spring to mind. The emergence of cell therapy has created an opportunity for a new wave of experts to pave the future. It’s the teams that think differently, embrace diversity and encourage new ideas that will propel themselves to the front of the pack.

A fair gender balance within cell therapy firstly gives an inevitable increased pool of talent and therefore access to more innovation and progression.

Secondly, a truly equal balance of male and female characteristics has been proven to make businesses, industries and even whole countries thrive. It’s for these reasons we celebrate the exceptional women in our sector ensuring one day their stories will become the norm.

 Michael

Thank you to Stacey Johnson of CCRM, Claudia Zylberberg of Akron Biotech and Susan Nichols of Invetech for their help in curating…

‘15 Influential Women in Cell & Gene Therapy’

Permission to Re-Publish

From: Michael Adeniya <michael@phacilitate.co.uk>

Date: Monday, July 11, 2016 at 5:51 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: Women Leaders in Cell and Gene Therapy | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

I hereby give you permission to publish the attached article titled ‘Women in cell & gene therapy’ 

Written by Michael Adeniya, Phacilitate Ltd 

Michael Adeniya

Tel:  +44 (0)20 7384 7951

Mob:  +44 (0)77 7932 7084

Email: michael@phacilitate.co.uk

Join our LinkedIn group Cell, Gene & Immunotherapy Leaders today!  

My initial Post included the following:

‘The Most Influential Women in Cell & Gene Therapy’

by

michael@phacilitate.co.uk

Full scale cell & gene therapy industrialisation is so close we can smell it. The sector is buzzing with innovation, sound business structure and plenty of interest from external stakeholders. From our perspective, it’s absolutely fascinating to watch. In the coming years, medicine will change dramatically. Major cell & gene therapy treatments will become the mainstay of doctor’s surgeries and hospitals. Healthcare leaders will be forced to consider a diverse portfolio of treatments for unmet medical needs. But we have a problem. Do a quick search on LinkedIn; you’ll see that some of the major cell therapy developers are bolstering their workforce. Juno have advertised over 30 new roles in 10 days, GSK, Mesoblast and Pfizer are also recruiting for a wide range of science-based roles. A ball-park count shows there could be over 1000 industrial cell & gene therapy roles being recruited for at the time of writing this. Research has shown time and again that diversity makes great business sense. Best-selling author Daniel Goleman advocates, the traits for successful leadership are knowledge and emotional intelligence, characteristics that transcend gender lines. Yet women continue to make up 4% of leadership roles. The disparity has been a subject of conversation at Davos this year and solutions are being discussed to attract talented females to this exciting and growing STEM industry. When we think of female science leaders, historical figures like Marie Curie and Rosalind Franklin tend to spring to mind. The emergence of cell therapy has created an opportunity for a new wave of to pave the future. It’s the teams that think differently, embrace diversity and encourage new ideas that will propel themselves to the front of the pack. A fair gender balance within cell therapy firstly gives an inevitable increased pool of talent and therefore access to more innovation and progression. Secondly, a truly equal balance of male and female characteristics has been proven to make businesses, industries and even whole countries thrive. It’s for these reasons we celebrate the exceptional women in our sector ensuring one day their stories will become ‘the norm’. Thank you to Stacey Johnson of CCRM, Claudia Zylberberg of Akron Biotech and Susan Nichols of Invetech for their help in curating: ‘The Most Influential Women in Cell & Gene Therapy

  1. Sandra Glucksmann – Editas
  2. Yael Margolin – Gamida Cell
  3. Claudia Zylberberg – Akron
  4. Connie Eaves – BC Cancer Agency
  5. Fiona Watt
  6. Janet Rossant
  7. Helen T. Martin – Adaptimmune
  8. Katherine A. High – Spark Therapeutics
  9. Linda Marbán – Capricor
  10. Kim Warren
  11. Linda Powers – NorthWest Biotherapeutics
  12. Molly Shoichet
  13. Sue Washer – AGTC
  14. Susan L. Solomon – NYSCF
  15. Tory Williams

SOURCE

Click to access women_in_cell_and_gene_therapy_phacilitate.pdf

Associations for women in science and technology:

http://www.womeninbio.org

 The Initiative on Women in Science and Engineering Working Group

http://www.westorg.org/

 Society for Canadian Women in Science and Technology (SCWIST)

 Canadian Coalition of Women in Engineering, Science, Trades and Technology (CCWESTT)

 Many universities have their own Centres for Women in Science, such as this one at Wilfrid Laurier University and this one at the University of Toronto

Read Full Post »

John Holdren tells Nature about the Highs and Lows of nearly eight years in the White House, Holdren is the longest-serving presidential Science Adviser in US history.

Reporter: Aviva Lev-Ari, PhD, RN

2.1.5.16

Article ID #205: John Holdren tells Nature, He is the longest-serving presidential Science Adviser in US history. Published on 7/7/2016

WordCloud Image Produced by Adam Tubman

2.1.5.16   John Holdren tells Nature about the Highs and Lows of nearly eight years in the White House, Holdren is the longest-serving presidential Science Adviser in US history, Volume 2 (Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology), Part 2: CRISPR for Gene Editing and DNA Repair

Obama’s top scientist talks shrinking budgets, Donald Trump, and his biggest regret

John Holdren tells Nature about the highs and lows of nearly eight years in the White House.

06 July 2016
 

Do you worry about future science funding?

The president has consistently recommended more money for science and technology than Congress has been willing to pass.

The success ratio of proposals to the NIH is something like 17% — that is, we are funding one-sixth of the proposals that the NIH gets. And those proposals are already self-selected. Investigators don’t bother writing a proposal to the NIH unless they think they have got a really good idea, a capable team and a plausible strategy. If you ask Francis Collins, the NIH director, what fraction of the proposals they get that are worthy of funding, he’ll tell you 50%.

That means we are funding about a third of the potentially productive, influential, path-breaking research that is proposed to the NIH. But the NIH has a budget of over US$30 billion per year. It’s not very easy in these budget times to increase a $30-billion budget by a large factor, like 50% — never mind 100% or more, as director Collins would say is warranted in terms of the quality of the research. The same is true at the National Science Foundation — far more worthy proposals than they are able to fund. This is a consistent problem. I would like to see more public support for raising public spending on research and development.

WATCH VIDEO

http://www.nature.com/news/obama-s-top-scientist-talks-shrinking-budgets-donald-trump-and-his-biggest-regret-1.20198?WT.mc_id=SFB_NNEWS_1508_RHBox

With Asilomar, every scientist working on recombinant DNA came together. But now there are researchers in China who are editing the human germ line using CRISPR, because it’s legal there — and there are plenty of others elsewhere. It’s arguably legal here.

And we’ve got high-school kids who can use CRISPR technology, so I’m not saying this is all tied up neatly with a bow. This is a very challenging question. When the technology is so widely available and so relatively easy to use, this is a very different matter than, for example, controlling nuclear-weapons technology. That has been a big challenge as well, as we know, but this is hard work.

Read more at Source

SOURCE

http://www.nature.com/news/obama-s-top-scientist-talks-shrinking-budgets-donald-trump-and-his-biggest-regret-1.20198?WT.mc_id=SFB_NNEWS_1508_RHBox

Read Full Post »

« Newer Posts - Older Posts »